Management of primary biliary cirrhosis

被引:302
作者
Heathcote, EJ [1 ]
机构
[1] Univ Toronto, Toronto Western Hosp, Univ Hlth Network, Div Gastroenterol, Toronto, ON M5T 2S8, Canada
关键词
D O I
10.1053/he.2000.5984
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Primary biliary cirrhosis (PBC) is a presumed autoimmune disease of the liver, which predominantly affects women once over the age of 20 years. Most cases are diagnosed when asymptomatic (60%). The antimitochondrial antibody is present in serum in most, but not in all, patients with PBC. The disease generally progresses slowly but survival is less than an age- and gender-matched general population. The symptomatic patient may have fatigue, generalized pruritus, portal hypertension, osteoporosis, skin xanthomata, fat soluble vitamin deficiencies, and/or recurrent asymptomatic urinary tract infections. Many nonhepatic autoimmune diseases are found in association with PBC and may prompt initial presentation. To date, immunosuppressive therapy has not been shown to prolong survival in PBC, The hydrophilic bile acid, ursodeoxycholic acid (UDCA), has been shown when given in a dose of 13 to 15 mg/kg daily for up to 4 years to delay the time to liver transplantation or death, This therapy also causes a significant improvement of all the biochemical markers of cholestasis but has no beneficial effects on any of the symptoms or associated disorders. Treatment with UDCA does not obviate the need for liver transplantation. Therapies to prevent complications arising from malabsorption, portal hypertension, and/or osteoporosis are required as well. Good control of pruritus can be achieved in most patients. PBC is diagnosed with increasing frequency, but the agent(s) responsible for this slowly progressive destruction of the interlobular bile ducts remains elusive and hence a specific therapy remains unavailable.
引用
收藏
页码:1005 / 1013
页数:9
相关论文
共 105 条
[1]   EFFECTS OF LONG-TERM RIFAMPICIN ADMINISTRATION IN PRIMARY BILIARY-CIRRHOSIS [J].
BACHS, L ;
PARES, A ;
ELENA, M ;
PIERA, C ;
RODES, J .
GASTROENTEROLOGY, 1992, 102 (06) :2077-2080
[2]  
BALAN V, 1993, HEPATOLOGY, V18, P1392
[3]   DIMINISHED SURVIVAL IN ASYMPTOMATIC PRIMARY BILIARY-CIRRHOSIS - A PROSPECTIVE-STUDY [J].
BALASUBRAMANIAM, K ;
GRAMBSCH, PM ;
WIESNER, RH ;
LINDOR, KD ;
DICKSON, ER .
GASTROENTEROLOGY, 1990, 98 (06) :1567-1571
[4]   AUTOIMMUNE CHOLANGIOPATHY - PART OF THE SPECTRUM OF AUTOIMMUNE CHRONIC ACTIVE HEPATITIS [J].
BENARI, Z ;
DHILLON, AP ;
SHERLOCK, S .
HEPATOLOGY, 1993, 18 (01) :10-15
[5]   EFFECTS OF NALOXONE INFUSIONS IN PATIENTS WITH THE PRURITUS OF CHOLESTASIS - A DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIAL [J].
BERGASA, NV ;
ALLING, DW ;
TALBOT, TL ;
SWAIN, MG ;
YURDAYDIN, C ;
TURNER, ML ;
SCHMITT, JM ;
WALKER, EC ;
JONES, EA .
ANNALS OF INTERNAL MEDICINE, 1995, 123 (03) :161-167
[6]   EFFECT OF DISTAL SPLENORENAL SHUNT ON SURVIVAL OF PATIENTS WITH PRIMARY BILIARY-CIRRHOSIS [J].
BOYER, TD ;
KOKENES, DD ;
HERTZLER, G ;
KUTNER, MH ;
HENDERSON, JM .
HEPATOLOGY, 1994, 20 (06) :1482-1486
[7]   PREVALENCE AND PATTERN OF FAMILIAL DISEASE IN PRIMARY BILIARY-CIRRHOSIS [J].
BRIND, AM ;
BRAY, GP ;
PORTMANN, BC ;
WILLIAMS, R .
GUT, 1995, 36 (04) :615-617
[8]   A CHOLANGITIS WITH ANTINUCLEAR ANTIBODIES (IMMUNOCHOLANGITIS) RESEMBLING CHRONIC DESTRUCTIVE NONSUPPURATIVE CHOLANGITIS [J].
BRUNNER, G ;
KLINGE, O .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1987, 112 (38) :1454-1458
[9]   BACTERIURIA AND PRIMARY BILIARY-CIRRHOSIS [J].
BURROUGHS, AK ;
ROSENSTEIN, IJ ;
EPSTEIN, O ;
HAMILTONMILLER, JMT ;
BRUMFITT, W ;
SHERLOCK, S .
GUT, 1984, 25 (02) :133-137
[10]   PRIMARY BILIARY-CIRRHOSIS AND ULCERATIVE-COLITIS [J].
BUSH, A ;
MITCHISON, H ;
WALT, R ;
BARON, JH ;
BOYLSTON, AW ;
SUMMERFIELD, JA .
GASTROENTEROLOGY, 1987, 92 (06) :2009-2013